iNtRON's Platform Technology
iNtRON's platform technology consists of PHAGERIARUS® technology to develop “Immune & Immunotherapeutics” and itLysin® to develop “Anti-Infectious Diseases Drugs”, PHAGERIA®, PHAGERUS®, and im-MucoDr® mRNA-related technologies.
We have expanded our Target Disease Area through long experience and verification. Our platform technologies can be divided into (1) “BC” (Before anti-Cancer Immunotherapeutics, Before Concept) Era before the development of “Immune & Immunotherapeutics” and (2) “AD” (After Anti-Infectious Disease Drugs, After New Definition/Doctrine) Era.
The core of PHAGERIARUS® is to view bacteriophages as foreign substances that invade the human body, such as bacteria and viruses. In other words, it presents a new perspective on the immune system in the human body in relation between bacteria, viruses, and bacteriophages. We are developing PHAGERIARUS® as a core technology for developing a number of immunotherapeutics, including immuno-cancer drugs, through the paradigm shift of existing immunology.
Our first development goal is immunotherapy for cancer. Immune regulators will be developed using our PHAGERIARUS® technology, resulting in immunotherapeutics. Furthermore, we will develop new drugs to treat various immune diseases, such as Alzheimer's, Parkinson's, and Diabetes using immune system regulators.
Development of a number of immunotherapeutics through the development of new BΦPTA or Immune Regulators based on ViP-Cycle
Development of treatments and vaccines targeting viral infectious diseases based on the similarity between bacteriophages and viruses
Development of new biopharmaceuticals targeting CRC, PD, and AD by regulating the gut microbiome with bacteriophages that respond to bacteria
Development of new biopharmaceuticals targeting bacterial infections including antibiotic-resistant bacteria by suing engineered endolysin based on itLysin® technology